Following a $100m private placement, Bavarian Nordic is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by the US and Canadian governments and Prostvac is advancing towards top-line Phase III data in 2017. The MVA-BN RSV vaccine is progressing towards mid-stage studies, while Phase II trials of CV-301 and Prostvac in combination with checkpoint inhibitors will start by mid-year. Our updated valuation of DKK13.4bn includes RSV and th
02 Jun 2016
Progressing at cruising speed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progressing at cruising speed
Bavarian Nordic A/S (BAVA:CSE) | 0 0 2.2% | Mkt Cap: 7,903m
- Published:
02 Jun 2016 -
Author:
Juan Pedro Serrate -
Pages:
12
Following a $100m private placement, Bavarian Nordic is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by the US and Canadian governments and Prostvac is advancing towards top-line Phase III data in 2017. The MVA-BN RSV vaccine is progressing towards mid-stage studies, while Phase II trials of CV-301 and Prostvac in combination with checkpoint inhibitors will start by mid-year. Our updated valuation of DKK13.4bn includes RSV and th